Air Force/Texas Coronary Atherosclerosis Prevention Study

Air Force/Texas Coronary Atherosclerosis Prevention Study. The AFCAPS/TexCAPS was a landmark randomized controlled trial published in 1998 that investigated the primary prevention of coronary artery disease. Conducted by researchers from the United States Air Force and the University of Texas Health Science Center at San Antonio, the study demonstrated that lovastatin therapy could significantly reduce the risk of first major coronary events in individuals with average cholesterol levels but low levels of high-density lipoprotein. Its findings fundamentally expanded the indicated population for statin therapy beyond those with overt hypercholesterolemia.

Background and Rationale

Prior to the late 1990s, major trials like the Scandinavian Simvastatin Survival Study (4S) and the West of Scotland Coronary Prevention Study (WOSCOPS) had established the benefit of statin drugs in secondary prevention and in primary prevention for men with high low-density lipoprotein levels. However, a significant clinical question remained regarding the large population of individuals with only moderately elevated LDL cholesterol but low levels of protective HDL cholesterol. The National Heart, Lung, and Blood Institute collaborated with the United States Air Force to design a trial addressing this specific, common lipid profile, hypothesizing that lovastatin could mitigate the risk of a first acute coronary syndrome in this under-studied group.

Study Design and Participants

AFCAPS/TexCAPS was a double-blind trial conducted primarily at Lackland Air Force Base and Wilford Hall Medical Center in Texas. It enrolled 6,605 generally healthy participants, including men aged 45 to 73 and postmenopausal women up to age 73. Key inclusion criteria required an average LDL cholesterol level and a below-average HDL cholesterol level, specifically excluding individuals with clinically evident atherosclerosis. Participants were randomly assigned to receive either daily lovastatin or a placebo and were followed for a median of 5.2 years, with primary endpoints including fatal or nonfatal myocardial infarction, unstable angina, and sudden cardiac death.

Major Findings and Results

The study, published in the Journal of the American Medical Association, reported a 37% reduction in the risk of suffering a first major acute coronary event in the lovastatin group compared to the placebo group. This benefit was observed without a significant difference in overall all-cause mortality between the two groups during the trial period. The results provided robust evidence that pharmacological intervention with a statin could effectively prevent initial cardiovascular disease events in a broad, primary prevention cohort with a common, moderate-risk lipid abnormality, a finding consistent with earlier trials like the Cholesterol and Recurrent Events trial but in a distinctly lower-risk population.

Clinical Significance and Impact

The findings of AFCAPS/TexCAPS had an immediate and profound impact on clinical practice guidelines for the prevention of coronary artery disease. It provided the evidence base for expanding statin therapy to millions of asymptomatic individuals with average LDL but low HDL, a group previously not targeted for intensive lipid-lowering. The study reinforced the importance of comprehensive lipid assessment beyond just total cholesterol and supported the therapeutic strategy of global risk reduction, influencing subsequent guidelines from the American College of Cardiology and the National Cholesterol Education Program.

Criticisms and Limitations

Some criticisms of the trial focused on the lack of a demonstrated mortality benefit, leading to debates about the cost-effectiveness and absolute risk reduction in a relatively low-risk population. The study population, drawn heavily from a United States Air Force cohort, was noted to be predominantly white and male, potentially limiting the generalizability of the findings to other demographic groups. Furthermore, the use of lovastatin, an earlier statin, raised questions about whether the results were fully applicable to more potent agents like atorvastatin or rosuvastatin that emerged later.

Legacy and Subsequent Research

AFCAPS/TexCAPS is regarded as a pivotal study that helped establish statins as a cornerstone of primary prevention for cardiovascular disease. It directly informed the design and rationale of later major trials such as the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which examined statin use in patients with elevated high-sensitivity C-reactive protein. The trial's legacy endures in modern risk assessment tools and treatment algorithms that incorporate HDL cholesterol levels and advocate for earlier, broader intervention to prevent atherosclerotic cardiovascular disease. Category:Clinical trials Category:Cardiology Category:1998 in science